Physician profile
Richard Pacca
NPI 1619189057
$3,423.37
in general payments reported to CMS, 2019-2025
29 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $539 · 2021: $142 · 2022: $93.93 · 2023: $248 · 2024: $425 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $507.18 | 2019-2022 | |
| Biotronik INC. | $381.58 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge |
| Boston Scientific Corporation | $336.70 | 2019-2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $299.65 | 2019-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $266.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $224.35 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.62 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $140.44 | 2019-2025 | Camzyos, Eliquis |
| Regeneron Healthcare Solutions, INC. | $136.72 | 2019 | |
| Lundbeck LLC | $117.00 | 2019-2020 | |
| Amgen INC. | $116.74 | 2019-2024 | Repatha |
| Amarin Pharma, INC. | $111.05 | 2019-2023 | |
| Pfizer INC. | $86.61 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.21 | 2019-2025 | Jardiance |
| Irhythm Technologies, INC. | $77.91 | 2019-2024 | Zio Xt Patch, Zio Monitor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $74.07 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.73 | 2019-2020 | |
| Esperion Therapeutics, INC. | $43.13 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $39.47 | 2024-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $18.42 | 2023 | Arcalyst |
| Celgene Corporation | $18.06 | 2024 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $16.08 | 2023 | Inpefa |
| Lilly USA, LLC | $15.17 | 2025 | Zepbound, Mounjaro |
| Sensible Medical Innovations INC | $14.41 | 2020 | |
| Mylan Specialty L.P. | $13.57 | 2020 | |
| Vifor Pharma, INC. | $12.03 | 2019 | |
| Edwards Lifesciences Corporation | $11.41 | 2019 | |
| Medtronic Vascular, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Pacca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.